Discover verified cancer discoveries

Search and filter stories that passed editorial review. Evidence strength, regulatory status, and guideline position are shown separately and are never inferred from one another.

Filter discoveries

Results

Active filters:Clear all

17 verified discoveries match your filters.

Trial Watch: A Study of Acalabrutinib vs Investigator’s Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL

Research type: Registered later-phase trialRegulatory status: Investigational
Cancer type
Leukemia
Published
October 23, 2026

ClinicalTrials.gov confirms that this Phase 3 study is registered and currently listed as Active Not Recruiting. This establishes the study's existence and registry-reported design/status, not a treatment benefit.

Primary source cited

Last reviewed

Trial Watch: Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia

Research type: Registered later-phase trialRegulatory status: Investigational
Cancer type
Leukemia
Published
October 23, 2026

ClinicalTrials.gov confirms that this Phase 3 study is registered and currently listed as Active Not Recruiting. This establishes the study's existence and registry-reported design/status, not a treatment benefit.

Primary source cited

Last reviewed

Trial Watch: Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma

Research type: Registered later-phase trialRegulatory status: Investigational
Cancer type
Leukemia, Lymphoma
Published
October 22, 2026

ClinicalTrials.gov confirms that this Phase 3 study is registered and currently listed as Active Not Recruiting. This establishes the study's existence and registry-reported design/status, not a treatment benefit.

Primary source cited

Last reviewed

Trial Watch: CINC424A2X01B Rollover Protocol

Research type: Registered later-phase trialRegulatory status: Investigational
Cancer type
Leukemia
Published
October 20, 2026

ClinicalTrials.gov confirms that this Phase 4 study is registered and currently listed as Active Not Recruiting. This establishes the study's existence and registry-reported design/status, not a treatment benefit.

Primary source cited

Last reviewed

Trial Watch: Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

Research type: Registered later-phase trialRegulatory status: Investigational
Cancer type
Leukemia
Published
October 19, 2026

ClinicalTrials.gov confirms that this Phase 3 study is registered and currently listed as Recruiting. This establishes the study's existence and registry-reported design/status, not a treatment benefit.

Primary source cited

Last reviewed

Trial Watch: Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

Research type: Registered later-phase trialRegulatory status: Investigational
Cancer type
Leukemia, Lymphoma
Published
September 17, 2026

ClinicalTrials.gov confirms that this Phase 3 study is registered and currently listed as Recruiting. This establishes the study's existence and registry-reported design/status, not a treatment benefit.

Primary source cited

Last reviewed

Trial Watch: A Study Evaluating Subcutaneous Versus Intravenous Blinatumomab in Newly Diagnosed Adults With B-cell Precursor Acute Lymphoblastic Leukaemia

Research type: Registered later-phase trialRegulatory status: Investigational
Cancer type
Leukemia
Published
September 16, 2026

ClinicalTrials.gov confirms that this Phase 3 study is registered and currently listed as Not Yet Recruiting. This establishes the study's existence and registry-reported design/status, not a treatment benefit.

Primary source cited

Last reviewed

Trial Watch: A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

Research type: Registered later-phase trialRegulatory status: Investigational
Cancer type
Leukemia
Published
August 29, 2026

ClinicalTrials.gov confirms that this Phase 3 study is registered and currently listed as Recruiting. This establishes the study's existence and registry-reported design/status, not a treatment benefit.

Primary source cited

Last reviewed

Trial Watch: Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation

Research type: Registered later-phase trialRegulatory status: Investigational
Cancer type
Leukemia
Published
August 28, 2026

ClinicalTrials.gov confirms that this Phase 3 study is registered and currently listed as Recruiting. This establishes the study's existence and registry-reported design/status, not a treatment benefit.

Primary source cited

Last reviewed